Benzinga··Vandana SinghPfizer's Next-Gen Pneumococcal Vaccine Shows Promise in Early Trials
Pfizer's experimental 25-valent pneumococcal vaccine demonstrates superior immune responses in Phase 2 data, advancing toward pivotal pediatric trials while planning a 35-valent adult candidate.
PFEPCVXPhase 3 trialPhase 2 data